Literature DB >> 9500609

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

N Ferrara1, H Chen, T Davis-Smyth, H P Gerber, T N Nguyen, D Peers, V Chisholm, K J Hillan, R H Schwall.   

Abstract

The development and endocrine function of the ovarian corpus luteum (CL) are dependent on the growth of new capillary vessels. Although several molecules have been implicated as mediators of CL angiogenesis, at present there is no direct evidence for the involvement of any. Here we report the unexpected finding that treatment with truncated soluble Flt-1 receptors, which inhibit vascular endothelial growth factor (VEGF) bioactivity, resulted in virtually complete suppression of CL angiogenesis in a rat model of hormonally induced ovulation. This effect was associated with inhibition of CL development and progesterone release. Failure of maturation of the endometrium was also observed. Areas of ischemic necrosis were demonstrated in the corpora lutea (CLs) of treated animals. However, no effect on the preexisting ovarian vasculature was observed. These findings demonstrate that, in spite of the redundancy of potential mediators, VEGF is essential for CL angiogenesis. Furthermore, they have implications for the control of fertility and the treatment of ovarian disorders characterized by hypervascularity and hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500609     DOI: 10.1038/nm0398-336

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  117 in total

Review 1.  Angiogenesis in the corpus luteum.

Authors:  L P Reynolds; A T Grazul-Bilska; D A Redmer
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

Review 2.  Vascular growth factors in cerebral ischemia.

Authors:  S D Croll; S J Wiegand
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

Review 3.  Angiogenesis in the female reproductive organs: pathological implications.

Authors:  Lawrence P Reynolds; Anna T Grazul-Bilska; Dale A Redmer
Journal:  Int J Exp Pathol       Date:  2002-08       Impact factor: 1.925

Review 4.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

5.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

6.  The long and short of the prolactin receptor: the corpus luteum needs them both!

Authors:  Carlos Stocco
Journal:  Biol Reprod       Date:  2012-03-22       Impact factor: 4.285

7.  Partial hepatectomy improves the outcome of intraportal islet transplantation by promoting revascularization.

Authors:  Yukihiko Saito; Nathaniel K Chan; Eba Hathout
Journal:  Islets       Date:  2012-03-01       Impact factor: 2.694

8.  Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.

Authors:  Napoleone Ferrara
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

9.  Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.

Authors:  De-Chao Yu; Jung-Sun Lee; Ji Young Yoo; Hyewon Shin; Hongxin Deng; Yuquan Wei; Chae-Ok Yun
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

10.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.